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Dear Colleagues,
The requirements associated with antidiabetic 
therapies are today much higher than in previous 
years. Currently, it is expected that antidiabetic drug 
not only will have potent glucose-lowering effect but 
also will be safe, especially with regard to cardiova-
scular risk. It is extremely important that patients with 
diabetes, who have been dying from cardiovascular 
diseases for many years, use drugs that do not increase 
cardiovascular risk. Further, it would be perfect if 
antidiabetic drugs contributed to reducing this risk. 
Since the announcement of the results of the EMPA-
-REG OUTCOME study, we know that this is possible. 
Empagliflozin was the first SGLT2 inhibitor for which, 
in addition to confirming its safety in patients with 
high-risk cardiovascular disease, cardiovascular risk 
reduction was also demonstrated. During the confe-
rence of the American Diabetes Association that will 
be held in San Diego, USA, from 9 to 13 June 2017, 
the results of the CANVAS and CANVAS R studies on 
the next flozin will be announced, which may bring us 
closer to answering the question whether beneficial 
impact of empagliflozin on the cardiovascular system 
is a class effect or is single molecule-specific. For those 
who will not be able to personally participate in this 
event, there is an opportunity to get answers to this 
and many other questions that may be of interest at 
the 6th Conference of the Journal of “Clinical Diabe-
tology”, which will be held in Warsaw on 23–24 June 
2017. Outstanding lecturers will also address many 
other topics related to the treatment of type 1 diabetes 
and will discuss with you whether the incretins and 
new basal insulin met our expectations. In addition to 
attending the scientific meetings, I also encourage you 
to read the latest issue of the “Clinical Diabetology”, 
where, among a number of interesting articles, I would 
like to draw your attention to the present-day problem 
of polypharmacy in elderly patients and to the original 
paper on the relationship between antidiabetic drugs 
and the risk of cancer. 
As usual, I invite you not only to read but also to 
actively contribute to the “Clinical Diabetology” and 
“Diabetologia Praktyczna” by submitting interesting 
papers as well as comments on the topics discussed 
in our journals.
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